Par End Period Cash Flow from 2010 to 2024

PAR Stock   294.05  12.65  4.50%   
Par Drugs' End Period Cash Flow is increasing over the years with slightly volatile fluctuation. Overall, End Period Cash Flow is expected to go to about 384.9 M this year. During the period from 2010 to 2024 Par Drugs End Period Cash Flow annual values regression line had geometric mean of  16,506,354 and mean square error of 6069.2 T. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
366.5 M
Current Value
384.9 M
Quarterly Volatility
137.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Par Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Par Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Total Revenue of 669.2 M or Gross Profit of 555.6 M, as well as many indicators such as . Par financial statements analysis is a perfect complement when working with Par Drugs Valuation or Volatility modules.
  
This module can also supplement various Par Drugs Technical models . Check out the analysis of Par Drugs Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.